Rubicon Research Receives Single Form 483 Observation for Satara Facility
Rubicon Research Ltd 路 Others (Uncategorized) 路 10 Oct 2026, 1:45 am
Rubicon Research Receives Single Form 483 Observation for Satara Facility The US FDA conducted an unannounced inspection at Rubicon Research鈥檚 manufacturing facility in Satara, Maharashtra, from 5th Oct'26 to 9th Oct'26. The audit concluded with the issuance of a Form 483 with one observation, which is procedural and does not involve data integrity. This marks the company's third unannounced US FDA inspection in FY27, following audits at its Toronto R&D site in Apr'26 and Pithampur facility in Jul'26. Rubicon remains confident in resolving the observation with the regulator promptly.
Original exchange filing (PDF)
More announcements from Rubicon Research Ltd
- Disclosure under Regulation 30 of SEBI LODR Regulations, 2015 (SEBI Regulations) w.r.t update on the Scheme of Merger between Rubicon Research Ltd and KIA Health Tech Pvt Ltd 路 14 Nov 2026
- Transcript of Earnings Call -Q2 - FY 2026-27 路 12 Nov 2026
- Audio Recording of Earnings confrence call for the Quarter ended 30th September, 2026 路 06 Nov 2026
- Monitoring Agency Report - Q2 ended September 2026 路 05 Nov 2026
- Investor Presentation for Q2 2026-27 路 05 Nov 2026
- Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Outcome of the Board Meeting held on November 5, 2026 路 05 Nov 2026
- Grant of Stock Options under Rubicon Research LImited Stock Option Plan 2026 路 05 Nov 2026
